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Background
Malignant Hyperthermia is pharmacogenetic disease
triggered by some anaesthetics such as halogenated
gases and non depolarizing muscle relaxant. The diag-
nosis of malignant hyperthermia susceptibility may be
done by 1) relevant clinical signs observed during the
crisis, 2) the in vitro contracture test (IVCT) with caf-
feine-halothane according to the European and the
American Malignant Hyperthermia Group protocols
and/or 3) the search for mutations of RYR 1 and CAC-
NA1S genes.
The IVCT identified three categories of patients: a)
MHS (malignant hyperthermia susceptible), b) MHE
(malignant hyperthermia equivocal) and c) MHN (non
susceptible).
A gene mutation may be defined as diagnostic only if
it can be defined as “causative mutations” capable to
alter the protein function in a cell culture test. The
patients carrying “no causative” mutations must carry
out the IVCT to confirm a susceptibility condition.
Usually, the first investigated patients, the probands,
have had an abnormal reactions during trigger anaesthesia
such as early signs (inappropriately elevated CO2, inap-
propriate tachycardia and/or arrhythmia and muscle signs
like masseter spasm or generalized muscle rigidity) or late
signs (rapid increase in core body temperature, high value
of CK etc). If the anaesthesia report has been well done it
is possible to attribute a Larach Clinical Grading Scale that
classifying the reactions as” almost certain” (more than 50
scores) or very rare “almost never” with 0 scores.
The susceptible probands may be also genetically stu-
died and the relatives warned of the genetic risk of an
autosomal dominant trait. The problems for the physicians
may be relevant when the probands have a raw score
range from 20 to 34 or more, and the IVCT results is
negative (MHN).
Although negative patients may be happy to result
negative, they remain worried regarding anaesthesia own
and of their relatives.
The worry for General Anesthesia (GA) does not disap-
pear with a negative test and it may be very difficult
explaining that other possible causes may be involved in
MH like reactions. In some MHN probands it may be
easier to find an explanation, as it is possible an alterna-
tive diagnosis or because…. the not clear or wrong anaes-
thetic report but what about the others. In some of
similar cases, we decide to perform a genetic analysis and
in one patient MHN patient we found a “no causative
mutation”. At this point the question is 1) can be assure
the MHN patients regarding GA with trigger agents?
2) Are there other possible investigations to give more
assurance to such patients? 3) genetic testing should be
prescribed also in the MHN probands?
We present the data of our MH laboratories highlight-
ing the IVCT and genetic results obtained on our pro-
bands and the suggestions and information that we give
to the MHN probands as well as some questions to the
auditorium.
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